| Overview |
| bs-4053R-PE |
| MAVS Polyclonal Antibody, PE Conjugated |
| WB |
| Mouse |
| Human, Rat, Cow |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MAVS |
| 3-100/540 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5788 |
| Cytoplasm |
| CARD adapter inducing interferon beta; Card; Interferon beta promoter stimulator protein 1; Interferon-beta promoter stimulator protein 1; Ips 1; Ips1; KIAA1271; Mitochondrial anti viral signaling protein; Mitochondrial Antiviral Signaling; Mitochondrial antiviral signaling protein; Putative NF kappa B activating protein 031N; Virus induced signaling adapter; DKFZp547C224; DKFZp666M015; FLJ27482; FLJ31698; FLJ35386; FLJ38051; CARD; FLJ41962; IPS-1; IPS1; MGC3260; VISA; MAVS_HUMAN. |
| MAVS (Mitochondrial Antiviral Signaling) mediates the activation of NF-kappaB and IRF3 in response to antiviral infection. Silencing of MAVS expression permits derepression of viral replication, while over expression of MAVS boosts antiviral immunity. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz